{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:34:41Z","timestamp":1751373281414},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T00:00:00Z","timestamp":1365120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T00:00:00Z","timestamp":1365120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40259-013-0028-3","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T08:26:07Z","timestamp":1365063967000},"page":"181-189","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Outlook for Alemtuzumab in Multiple Sclerosis"],"prefix":"10.1007","volume":"27","author":[{"given":"Thomas","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair","family":"Coles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Azzopardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,5]]},"reference":[{"key":"28_CR1","volume-title":"Atlas\u2014multiple sclerosis resources in the world","author":"World Health Organisation and Multiple Sclerosis International Federation","year":"2008","unstructured":"World Health Organisation and Multiple Sclerosis International Federation. Atlas\u2014multiple sclerosis resources in the world. Geneva: WHO Press; 2008."},{"issue":"7359","key":"28_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"International Multiple Sclerosis Genetics Consortium","year":"2011","unstructured":"International Multiple Sclerosis Genetics Consortium, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214\u20139.","journal-title":"Nature"},{"issue":"9648","key":"28_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet"},{"issue":"8","key":"28_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/brain\/awq176","volume":"133","author":"JL Jones","year":"2010","unstructured":"Jones JL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133(8):2232\u201347.","journal-title":"Brain"},{"issue":"5","key":"28_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"BD Trapp","year":"1998","unstructured":"Trapp BD, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278\u201385.","journal-title":"N Engl J Med"},{"issue":"5","key":"28_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/jnnp.50.5.511","volume":"50","author":"NM Milligan","year":"1987","unstructured":"Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1 clinical effects. J Neurol Neurosurg Psychiatry. 1987;50(5):511\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"28_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.51.2.529","volume":"51","author":"F Sellebjerg","year":"1998","unstructured":"Sellebjerg F, et al. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology. 1998;51(2):529\u201334.","journal-title":"Neurology"},{"issue":"4","key":"28_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","author":"P Duquette","year":"1993","unstructured":"Duquette P, et al. Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis\u2014clinical-results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655\u201361.","journal-title":"Neurology"},{"issue":"7","key":"28_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","volume":"45","author":"The IFNB Multiple Sclerosis Study Group","year":"1995","unstructured":"The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS\/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277\u201385.","journal-title":"Neurology"},{"issue":"3","key":"28_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285\u201394.","journal-title":"Ann Neurol"},{"issue":"9139","key":"28_CR11","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","year":"1998","unstructured":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. The Lancet. 1998;352(9139):1498\u2013504.","journal-title":"The Lancet"},{"issue":"3","key":"28_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jama.2012.7625","volume":"308","author":"A Shirani","year":"2012","unstructured":"Shirani A, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012;308(3):247\u201356.","journal-title":"JAMA"},{"issue":"7","key":"28_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJM198708133170703","volume":"317","author":"MB Bornstein","year":"1987","unstructured":"Bornstein MB, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987;317(7):408\u201314.","journal-title":"N Engl J Med"},{"issue":"7","key":"28_CR14","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"KP Johnson","year":"1995","unstructured":"Johnson KP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268\u201376.","journal-title":"Neurology"},{"issue":"10","key":"28_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","volume":"7","author":"DD Mikol","year":"2008","unstructured":"Mikol DD, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis [the REbif vs Glatiramer Acetate in Relapsing MS Disease (REGARD) study]: a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903\u201314.","journal-title":"Lancet Neurol"},{"issue":"23","key":"28_CR16","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/01.wnl.0000345970.73354.17","volume":"72","author":"D Cadavid","year":"2009","unstructured":"Cadavid D, et al. Efficacy of treatment of MS with IFN beta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72(23):1976\u201383.","journal-title":"Neurology"},{"issue":"5741","key":"28_CR17","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1126\/science.1113640","volume":"309","author":"SR Schwab","year":"2005","unstructured":"Schwab SR, et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005;309(5741):1735\u20139.","journal-title":"Science"},{"issue":"11","key":"28_CR18","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"L Kappos","year":"2006","unstructured":"Kappos L, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124\u201340.","journal-title":"N Engl J Med"},{"issue":"2","key":"28_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1073\/pnas.1014154108","volume":"108","author":"JW Choi","year":"2011","unstructured":"Choi JW, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA. 2011;108(2):751\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"28_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387\u2013401.","journal-title":"N Engl J Med"},{"issue":"5","key":"28_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402\u201315.","journal-title":"N Engl J Med"},{"issue":"9","key":"28_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911\u201323.","journal-title":"N Engl J Med."},{"issue":"11","key":"28_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology"},{"issue":"9","key":"28_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924\u201333.","journal-title":"N Engl J Med"},{"issue":"4","key":"28_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438\u201346.","journal-title":"Lancet Neurol"},{"issue":"20","key":"28_CR26","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870\u201380.","journal-title":"N Engl J Med"},{"issue":"14","key":"28_CR27","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","volume":"69","author":"PA Calabresi","year":"2007","unstructured":"Calabresi PA, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391\u2013403.","journal-title":"Neurology"},{"key":"28_CR28","unstructured":"Abbott. Annual report (online). http:\/\/www.abbott.com\/static\/content\/microsite\/annual_report\/2010\/docs\/Abbott_AR2010_Financials.pdf (2010)."},{"issue":"2","key":"28_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S1359-6446(03)02953-2","volume":"9","author":"AJ Chirino","year":"2004","unstructured":"Chirino AJ, Ary ML, Marshall SA. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today. 2004;9(2):82\u201390.","journal-title":"Drug Discov Today"},{"issue":"7","key":"28_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"28_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348(7):601\u20138.","journal-title":"N Engl J Med"},{"issue":"11","key":"28_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","volume":"28","author":"AS De Groot","year":"2007","unstructured":"De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28(11):482\u201390.","journal-title":"Trends Immunol"},{"issue":"10","key":"28_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3229","volume":"9","author":"AL Nelson","year":"2010","unstructured":"Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9(10):767\u201374.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"28_CR34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V62.4.873.873","volume":"62","author":"G Hale","year":"1983","unstructured":"Hale G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983;62(4):873\u201382.","journal-title":"Blood"},{"issue":"6162","key":"28_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/332323a0","volume":"332","author":"L Riechmann","year":"1988","unstructured":"Riechmann L, et al. Reshaping human antibodies for therapy. Nature. 1988;332(6162):323\u20137.","journal-title":"Nature"},{"issue":"6","key":"28_CR36","doi-asserted-by":"publisher","first-page":"e39416","DOI":"10.1371\/journal.pone.0039416","volume":"7","author":"SP Rao","year":"2012","unstructured":"Rao SP, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS ONE. 2012;7(6):e39416.","journal-title":"PLoS ONE"},{"issue":"1","key":"28_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/intimm\/7.1.69","volume":"7","author":"WC Rowan","year":"1995","unstructured":"Rowan WC, et al. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol. 1995;7(1):69\u201377.","journal-title":"Int Immunol"},{"issue":"3","key":"28_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clim.2006.05.006","volume":"120","author":"T Watanabe","year":"2006","unstructured":"Watanabe T, et al. CD52 is a novel costimulatory molecule for induction of CD4(+) regulatory T cells. Clin Immunol. 2006;120(3):247\u201359.","journal-title":"Clin Immunol"},{"issue":"8625","key":"28_CR39","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/S0140-6736(88)90588-0","volume":"2","author":"G Hale","year":"1988","unstructured":"Hale G, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988;2(8625):1394\u20139.","journal-title":"Lancet"},{"issue":"10","key":"28_CR40","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554\u201361.","journal-title":"Blood"},{"issue":"11","key":"28_CR41","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1432-2277.2006.00388.x","volume":"19","author":"RN Barth","year":"2006","unstructured":"Barth RN, et al. Outcomes at 3\u00a0years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int. 2006;19(11):885\u201392.","journal-title":"Transpl Int"},{"issue":"1","key":"28_CR42","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/asheducation-2002.1.392","volume":"2002","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, et al. Non-myeloablative transplantation. Hematol Am Soc Hematol Educ Program. 2002;2002(1):392\u2013421.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"12","key":"28_CR43","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/qjmed\/89.12.903","volume":"89","author":"CM Lockwood","year":"1996","unstructured":"Lockwood CM, et al. Treatment of refractory Wegener\u2019s granulomatosis with humanized monoclonal antibodies. QJM. 1996;89(12):903\u201312.","journal-title":"QJM"},{"issue":"8918","key":"28_CR44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(94)91339-0","volume":"344","author":"T Moreau","year":"1994","unstructured":"Moreau T, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 1994;344(8918):298\u2013301.","journal-title":"Lancet"},{"issue":"3","key":"28_CR45","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","volume":"46","author":"AJ Coles","year":"1999","unstructured":"Coles AJ, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46(3):296\u2013304.","journal-title":"Ann Neurol"},{"issue":"1","key":"28_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","volume":"253","author":"AJ Coles","year":"2006","unstructured":"Coles AJ, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253(1):98\u2013108.","journal-title":"J Neurol"},{"issue":"17","key":"28_CR47","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"Camms Trial Investigators","year":"2008","unstructured":"Camms Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786\u2013801.","journal-title":"N Engl J Med"},{"issue":"14","key":"28_CR48","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","volume":"78","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology. 2012;78(14):1069\u201378.","journal-title":"Neurology"},{"issue":"9856","key":"28_CR49","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet. 2012;380(9856):1819\u201328.","journal-title":"The Lancet"},{"key":"28_CR50","unstructured":"Genzyme, Alemtuzumab (Lemtrada\u2122*) significantly reduces relapses in multiple sclerosis vs interferon beta-1a in a phase III study, 2011: http:\/\/www.reuters.com\/article\/2011\/10\/22\/idUS29431+22-Oct-2011+BW20111022."},{"issue":"9856","key":"28_CR51","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles, AJ, et al, Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829\u201339.","journal-title":"Lancet"},{"key":"28_CR52","unstructured":"Genzyme, Significant improvement in disability scores observed in multiple sclerosis patients who received Lemtrada\u2122* (alemtuzumab) compared with rebif\u00ae in phase III trial, 2012. http:\/\/www.reuters.com\/article\/2012\/04\/24\/idUS217878+24-Apr-2012+BW20120424."},{"issue":"3","key":"28_CR53","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2125.2007.02914.x","volume":"64","author":"DR Mould","year":"2007","unstructured":"Mould DR, et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol. 2007;64(3):278\u201391.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"28_CR54","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1002\/eji.200535075","volume":"35","author":"AL Cox","year":"2005","unstructured":"Cox AL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332\u201342.","journal-title":"Eur J Immunol"},{"issue":"1","key":"28_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","volume":"30","author":"SA Thompson","year":"2010","unstructured":"Thompson SA, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99\u2013105.","journal-title":"J Clin Immunol"},{"issue":"9191","key":"28_CR56","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"354","author":"AJ Coles","year":"1999","unstructured":"Coles AJ, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691\u20135.","journal-title":"Lancet"},{"issue":"9144","key":"28_CR57","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(05)60398-4","volume":"352","author":"J Gilquin","year":"1998","unstructured":"Gilquin J, et al. Delayed occurrence of Graves\u2019 disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet. 1998;352(9144):1907\u20138.","journal-title":"Lancet"},{"issue":"7","key":"28_CR58","first-page":"2052","volume":"119","author":"JL Jones","year":"2009","unstructured":"Jones JL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052\u201361.","journal-title":"J Clin Invest"},{"issue":"1","key":"28_CR59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/brain\/119.1.225","volume":"119 (Pt 1)","author":"T Moreau","year":"1996","unstructured":"Moreau T, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996;119 (Pt 1)(1):225\u201337.","journal-title":"Brain"},{"issue":"8","key":"28_CR60","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1046\/j.1365-2168.2000.01504.x","volume":"87","author":"JL Kraimps","year":"2000","unstructured":"Kraimps JL, et al. Multicentre study of thyroid nodules in patients with Graves\u2019 disease. Br J Surg. 2000;87(8):1111\u20133.","journal-title":"Br J Surg"},{"issue":"6","key":"28_CR61","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1365-2265.2004.02043.x","volume":"60","author":"WB Kim","year":"2004","unstructured":"Kim WB, et al. Ultrasonographic screening for detection of thyroid cancer in patients with Graves\u2019 disease. Clin Endocrinol (Oxf). 2004;60(6):719\u201325.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"28_CR62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12020-010-9405-6","volume":"39","author":"D Berker","year":"2011","unstructured":"Berker D, et al. Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism. Endocrine. 2011;39(1):13\u201320.","journal-title":"Endocrine"},{"issue":"1","key":"28_CR63","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4049\/jimmunol.1000422","volume":"185","author":"J Somerfield","year":"2010","unstructured":"Somerfield J, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol. 2010;185(1):763\u20138.","journal-title":"J Immunol"},{"key":"28_CR64","unstructured":"McCarthy C, et al. Immune Responses to Vaccination in Multiple Sclerosis Patients Post-alemtuzumab Treatment (CAM-VAC study (poster). In: 5th Joint triennial congress of the European and Americas Committees for treatment and research in multiple sclerosis. Amsterdam: The Netherlands; 2011."},{"key":"28_CR65","unstructured":"Discontinuation of licensed supplies of alemtuzumab (Mabcampath). 8 Aug 2012: National electronic Library for Medicines."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0028-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-013-0028-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0028-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0028-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T13:24:26Z","timestamp":1659101066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-013-0028-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,5]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["28"],"URL":"https:\/\/doi.org\/10.1007\/s40259-013-0028-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,5]]},"assertion":[{"value":"5 April 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}